GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Windlas Biotech Ltd

Windlas Biotech Q2 FY27 Net Profit at INR 180.52 million; Management Changes Noted

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 05 Nov 2026, 04:18 PM IST  ·  BSE ID: 027f8b04-8b8f-4756-a726-2ef93a472796
View Original BSE Filing (PDF)
💡
In Simple Terms
Windlas Biotech released its Q2 FY27 financial results, showing a net profit of INR 180.52 million, alongside key leadership changes.
🤖 AI Summary
  • Windlas Biotech reported unaudited net profit of INR 180.52 million for the quarter ended September 30, 2026 (Q2 FY27).
  • Revenue from operations reached INR 2,639.08 million for Q2 FY27, contributing to a half-year revenue of INR 5,120.07 million.
  • Mr. Ashok Kumar Windlass resigned as Whole-time Director, effective November 5, 2026, and was appointed Senior Management Personnel.
  • Mr. Hitesh Windlass, Managing Director and Promoter, was appointed as the Chairman of the Board, effective November 5, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
INR 2,639.08 million
Profit for the Period (Q2 FY27)
INR 180.52 million
1.42
Revenue from Operations (Half Year FY27)
INR 5,120.07 million
18.40
Profit for the Period (Half Year FY27)
INR 357.05 million
0.68
Basic EPS (Q2 FY27)
Rs. 8.75
3.18
🏢 How This Affects the Company
💰
Financial Impact
The company's net profit for Q2 FY27 was INR 180.52 million, with revenue from operations at INR 2,639.08 million for the same quarter.
⚙️
Operational Impact
Management changes, including the appointment of a new Board Chairman and a former Whole-time Director transitioning to Senior Management, indicate a reorganization of leadership roles within the company.
⚠️
Risk Impact
The dissolution of Windlas Inc., USA, a wholly owned non-operating subsidiary, with effect from March 31, 2026, simplifies the company's structure by eliminating the need for consolidated financial statements from April 1, 2026.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with Basic EPS at Rs. 8.75 for Q2 FY27 and Rs. 17.21 for the half-year ended September 30, 2026. The changes in board and senior management personnel impact overall corporate governance.
🔍
Management Signal
The Board's actions signal a focus on long-term succession planning and a consolidation of leadership roles, with the Managing Director also assuming the Chairman position.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — observe revenue and profit trends.
Shareholder approval for Mr. Ashok Kumar Windlass's appointment as Senior Management Personnel.
Any further announcements regarding management or board restructuring.
LOW RISK The filing reports routine financial results and management changes without significant identified risks.
💡 Investor Takeaway
Windlas Biotech reported Q2 FY27 net profit of INR 180.52 million, with half-year revenue at INR 5,120.07 million. Mr. Hitesh Windlass is now Chairman, and Mr. Ashok Kumar Windlass transitioned to Senior Management Personnel, indicating management succession planning.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from operations for the half year ended September 30, 2026, was INR 5,120.07 million, an increase from INR 4,324.88 million in the prior half year.
  • Profit for the half year ended September 30, 2026, was INR 357.05 million, compared to INR 354.65 million in the prior half year.

⚠️ Concerns

  • Profit before tax for Q2 FY27 was INR 233.00 million, a slight decrease from INR 235.88 million in Q2 FY26.
  • Half-year profit before tax for September 30, 2026, was INR 462.36 million, down from INR 468.46 million in the prior half year.
📅 Company Track Record
The company completed a buyback of 470,000 equity shares at Rs. 1,000 per share, aggregating to Rs. 470,000,000, as per a Board Resolution dated April 17, 2026. A dividend of Rs. 6.30 per share for the year ended March 31, 2026, amounting to Rs. 130.01 million, was approved by shareholders on July 23, 2026, and paid on July 31, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Windlas Biotech's net profit for the quarter ended September 30, 2026?
Windlas Biotech reported a net profit of INR 180.52 million for the quarter ended September 30, 2026 (Q2 FY27).
What was Windlas Biotech's revenue from operations for Q2 FY27?
The revenue from operations for Windlas Biotech for the quarter ended September 30, 2026, was INR 2,639.08 million.
Who has been appointed as the new Chairman of Windlas Biotech's Board?
Mr. Hitesh Windlass, the Managing Director and Promoter, has been appointed as the Chairman of the Board of Directors for Windlas Biotech, effective November 5, 2026.
What is the status of Windlas Inc., USA, a subsidiary of Windlas Biotech?
Windlas Inc., USA, a wholly owned non-operating subsidiary, was dissolved with effect from March 31, 2026. Consequently, consolidated financial statements are not prepared from April 1, 2026.
What is Windlas Biotech's Basic Earnings Per Share for Q2 FY27?
Windlas Biotech's Basic Earnings Per Share for the quarter ended September 30, 2026, was Rs. 8.75.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.